At an international level, staggering differences emerge over three years: A 139.7% success story vs. a -28.6% failure narrative
In the financial landscape, Constellation Software, a prominent software and service provider, has shown a significant surge in its international earnings over the past three years, climbing by an impressive 139.7 percent. Contrastingly, a notable player in the European market, Biogen, has grappled with a 28.6 percent decline during the same period.
Canadian-based Constellation Software employs a "buy-and-build" strategy, acquiring and further developing small, complementary companies that exhibit robust management, above-average growth, and consistent profitability. For potential acquisitions, the company seeks companies with a minimum annual turnover of five million dollars and a substantial customer base. By bundling hundreds of companies into six operational units focused on specific industries, Constellation Software utilizes free cash flow for additional acquisitions, fostering a steady growth in profits while maintaining manageable debt levels.
Founder Mark Leonard has led Constellation Software since 1995, and the company will release its fourth-quarter 2024 financial results on March 7.
Meanwhile, the much-anticipated Alzheimer's treatment from Biogen and Eisai, Lecanemab, remains under review by the European Medicines Agency (EMA). Despite a November recommendation for approval, the EU commission announced further assessments are necessary before granting the green light. The antibody, intended for the treatment of mild dementia in early-stage Alzheimer's patients, is already available in the United States. The ongoing delay in the EU has led to a 28.6 percent decrease in Biogen's stock price, despite a sharp rise in 2022 due to promising research results. Additionally, Biogen's multiple sclerosis drug business is experiencing a decline. Several analysts have adjusted their earnings expectations and price targets for the coming period, with TD Cowen citing slower-than-expected product launches.
A comprehensive financial analysis for Constellation Software, based on its most recent quarterly results, reveals steady revenue growth (up by 13 percent in Q1 2025 compared to Q1 2024), robust net income, and manageable debt levels. Biogen's most recent comparable quarterly results are not detailed in the provided sources.
Readers are encouraged to follow national and international financial trends by regularly checking the TOPS and FLOPS in the weekly, one-year, and three-year editions of €uro am Sonntag, a reputable financial newspaper. Every week, this publication offers insightful news, trends, and analysis to aid informed investment decisions.
In the latest issue, there are further compelling topics, including a discussion on defense stocks, such as Rheinmetall, Hensoldt, and Leonardo, skyrocketing due to their promising performance. The impact of artificial intelligence on the recently sluggish sales of the iPhone series is also examined, alongside a Saudi Arabian-Kim Kardashian collaboration that boosted the previously stagnant stock of a sportswear company. Additionally, the paper delves into the volatile stock of a battery manufacturer and the continued optimism of a Wall Street legend amidst oil price pressures.
Since 1998, €uro am Sonntag has been a trusted source of market information and insights, helping readers stay informed about financial movements and their potential impact on their investments. Each Saturday at 6 PM, digital subscribers receive an additional update with relevant updates and supplements, including closing prices of the Frankfurt and New York stock exchanges, and an exclusive overview of the week's most traded derivatives.
Readers can access €uro am Sonntag, including the update, in a digital promotional subscription for just 9.90 Euros, saving over 25 percent. This offer includes three digital issues.
Constellation Software, with its focus on the buy-and-build strategy, has been actively involved in investing in and expanding small businesses within the business sector, aiming to achieve growth and profitability. On the contrary, Biogen, a player in the European market, has experienced a decline in its stock price due to the delay in the approval of its anticipated Alzheimer's treatment and the decline in its multiple sclerosis drug business.
